← SynDRA
CI-1040
SynDRA canonical compound SYN0003943 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MAP2K1 |
|---|
| Mechanism of action | MEK inhibitor |
|---|
All known targets
- MAP2K1
- MAP2K2
- MAP3K1
- MAP3K2
Mechanisms of action (all sources)
- MEK inhibitor
- MAP2K1 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- MAP2K2 INHIBITOR
- Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
- MAP2K1 NEGATIVE ALLOSTERIC MODULATOR
Cross-references
Synonyms
- PD-18435
- PD-184352
- PD 184352
- R3K9Y00J04
- RefChem:453552
- PD184352
- PD184352 (CI-1040)
- C17H14ClF2IN2O2
- MFCD02683961
- C.I. 1040
- NCGC00189074-01
- DTXCID5028871
- CI1040
- CAS-212631-79-3
- PD 184352(CI-1040)
- MLS006010176
- SCHEMBL570330
- UNII-R3K9Y00J04
- PD 184352, Free Base
- GTPL5676
- orb1305479
- SCHEMBL29355105
- SCHEMBL29381365
- CHEBI:91353
- CI 1040 [WHO-DD]
- GLXC-07276
- HMS3244G05
- HMS3244G06
- HMS3244H05
- HMS3265I07
- HMS3265I08
- HMS3265J07
- HMS3265J08
- HMS3654I05
- EX-A2202
- Tox21_113363
- BDBM50132260
- EBC-11308
- NSC765695
Look up CI-1040 in the interactive SynDRA portal →